Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 6/20 | 0.54 |
| ▸ | CDK1 | P06493 | 5/20 | 0.50 |
| ▸ | MARK3 | P27448 | 3/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.50 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.50 |
| ▸ | AXL | P30530 | 3/20 | 0.50 |
| ▸ | IGF1R | P08069 | 2/20 | 0.50 |
| ▸ | JAK2 | O60674 | 2/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.50 |
| ▸ | AURKA | O14965 | 2/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.50 |
| ▸ | LYN | P07948 | 2/20 | 0.50 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.50 |
| ▸ | BLK | P51451 | 2/20 | 0.50 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.50 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.50 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 0.50 |
| ▸ | PLK3 | Q9H4B4 | 2/20 | 0.50 |
| ▸ | KDR | P35968 | 2/20 | 0.50 |
| ▸ | GSK3B | P49841 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6882453 | 0.83 | AURKA (0.55) | CDK1FGFR3AURKALCKFLT3 | |
| SCHEMBL17604427 | 0.77 | SYK (0.58) | FGFR1JAK2KDRSRCSYK | |
| SCHEMBL14287382 | 0.77 | AURKA (0.44) | CDK2CDK1AURKAKDRSYK | |
| SCHEMBL3415683 | 0.77 | CDK2 (0.55) | CDK2CDK1MARK3FGFR1FGFR3 | |
| SCHEMBL30219533 | 0.77 | ATM (0.48) | CDK1AXLJAK2RPS6KB1ERBB4 | |
| SCHEMBL28986320 | 0.77 | ATM (0.48) | CDK1AXLJAK2RPS6KB1ERBB4 | |
| SCHEMBL3429733 | 0.76 | SYK (0.59) | CDK1CDK5AURKASYKLRRK2 | |
| SCHEMBL5264282 | 0.76 | CDK4 (0.52) | CDK2CDK1MARK3FGFR1FGFR3 | |
| SCHEMBL25016924 | 0.75 | RPS6KA3 (0.47) | AURKARPS6KA3SYK | |
| SCHEMBL13735129 | 0.75 | JAK1 (0.53) | JAK2AURKATYK2JAK3PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | claimed |
| US-20130303563-A1 | TREATMENT OF PERITONEAL INJURY USING JAK INHIBITORS | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER | 2013-11-14 | — | — | US | claimed |
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | disclosed |
| US-20160193203-A1 | TREATMENT OF PERITONEAL INJURY USING JAK INHIBITORS | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER | 2016-07-07 | — | — | US | disclosed |
| US-9198900-B2 | Treatment of peritoneal injury using JAK inhibitors | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2015-12-01 | — | — | US | disclosed |
| US-20130303563-A1 | TREATMENT OF PERITONEAL INJURY USING JAK INHIBITORS | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER | 2013-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | MAP3K20, MAP3K15, MAP3K1 | CDK2 253/4885CDK1 267/4885MARK3 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.